Anika Therapeutics Inc
NASDAQ:ANIK

Watchlist Manager
Anika Therapeutics Inc Logo
Anika Therapeutics Inc
NASDAQ:ANIK
Watchlist
Price: 9.56 USD 0.74% Market Closed
Market Cap: 137.9m USD

Wall Street
Price Targets

ANIK Price Targets Summary
Anika Therapeutics Inc

Wall Street analysts forecast ANIK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANIK is 16.32 USD with a low forecast of 16.16 USD and a high forecast of 16.8 USD.

Lowest
Price Target
16.16 USD
69% Upside
Average
Price Target
16.32 USD
71% Upside
Highest
Price Target
16.8 USD
76% Upside
Anika Therapeutics Inc Competitors:
Price Targets
LENZ
Graphite Bio Inc
196% Upside
PTCT
PTC Therapeutics Inc
10% Upside
ATX
Amplia Therapeutics Ltd
230% Upside
DVYSR
Devyser Diagnostics AB
41% Upside
688180
Shanghai Junshi Biosciences Co Ltd
28% Downside
CGON
CG Oncology Inc
79% Upside
NRIX
Nurix Therapeutics Inc
45% Upside
CVAC
CureVac NV
5% Downside

Revenue
Forecast

Revenue Estimate
Anika Therapeutics Inc

For the last 13 years the compound annual growth rate for Anika Therapeutics Inc's revenue is 5%. The projected CAGR for the next 3 years is 1%.

5%
Past Growth
1%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Anika Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Anika Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ANIK's stock price target?
Price Target
16.32 USD

According to Wall Street analysts, the average 1-year price target for ANIK is 16.32 USD with a low forecast of 16.16 USD and a high forecast of 16.8 USD.

What is Anika Therapeutics Inc's Revenue forecast?
Projected CAGR
1%

For the last 13 years the compound annual growth rate for Anika Therapeutics Inc's revenue is 5%. The projected CAGR for the next 3 years is 1%.

Back to Top